Cord blood stem cell therapy - CellPraxis
Latest Information Update: 04 Feb 2016
At a glance
- Originator CellPraxis
- Class Antirheumatics; Stem cell therapies
- Mechanism of Action Cell replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Amyotrophic lateral sclerosis
Most Recent Events
- 31 Oct 2012 Phase-I/II clinical trials in Amyotrophic lateral sclerosis in Brazil (IV)